國家衛生研究院 NHRI:Item 3990099045/10597
English  |  正體中文  |  简体中文  |  全文筆數/總筆數 : 12145/12927 (94%)
造訪人次 : 916465      線上人數 : 1428
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
搜尋範圍 查詢小技巧：
  • 您可在西文檢索詞彙前後加上"雙引號"，以獲取較精準的檢索結果
  • 若欲以作者姓名搜尋，建議至進階搜尋限定作者欄位，可獲得較完整資料
    •  進階搜尋
    主頁 ‧ 登入 ‧ 上傳 ‧ 說明 ‧ 關於NHRI ‧ 管理 到手機版


    請使用永久網址來引用或連結此文件: http://ir.nhri.org.tw/handle/3990099045/10597


    題名: A molecular modeling-based investigation of the intermolecular interactions between the different Her2 receptor tyrosine kinase mutant variants and clinical small molecules in lung cancer
    作者: Gow, CH;Liu, YC
    貢獻者: Division of Biostatistics and Bioinformatics
    摘要: HER2 is a major proliferative driver in lung cancer and the role of HER2-targeting drugs for cancer treatment remains Introduction: unclear. Case series have reported lung adenocarcinoma patients with mutations response to certain tyrosine kinase inhibitors. HER2 However, whether all types of mutations may have similar reposes to anti-HER targeted therapy is yet to be established. HER2 The crystal structure of wild-type HER2 (HER2) kinase domain from the Protein Data Bank database (3PP0) was retrieved. Methods: WT Mutant HER2 amino acids sequences curated from the UniProt database and the sequences were then aligned to each other using ClustalW program. We applied homology remodeling and molecular docking methods to investigate the intermolecular interaction and affinity between variants (wild-type [HER2], A775_G776insYVMA [HER2 ], P780_Y781insGSP [HER2], HER2 WT YVMA GSP A775_V777delG776insLC [HER2],and L755P [HER2 ]) and tyrosine kinase inhibitors (afatinib, lapatinib, and neratinib). LC L755P : We observed that these three inhibitors exhibit differentiated selectivity between the HER2 and HER2 variants. HER2 had Results WT GSP relative lower affinity to lapatinib but was able to sensitize neratinib. HER2 failed to sensitize lapatinib, afatinib, and neratinib. It was YVMA found that HER2 and HER2 cannot sensitize lapatinib and afatinib, but may enhance inhibitory capability of neratinib. Finally, LC L755P afatinib possessed better potency against HER2 than HER2 ; neratinib conferred stronger drug sensitivity to HER2 , HER2, GSP YVMA GSP LC and HER2 , but not HER2 variants. L755P YVMA Different mutant variants may have various reposes to individual tyrosine kinase inhibitors. Understanding of the Conclusion: HER2 HER2 mutant protein—small molecule interactions and factors affecting atomic affinity can be helpful to conduct further research on the rational design of more potent therapeutic agents.
    日期: 2017-05
    關聯: American Journal of Respiratory and Critical Care Medicine. 2017 May;195:A7538.
    JIF/Ranking 2023: http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=1073-449X&DestApp=IC2JCR
    Cited Times(WOS): https://www.webofscience.com/wos/woscc/full-record/WOS:000400372507640
    顯示於類別:[其他] 會議論文/會議摘要

    文件中的檔案:

    檔案 描述 大小格式瀏覽次數
    ISI000400372507640.pdf19KbAdobe PDF363檢視/開啟


    在NHRI中所有的資料項目都受到原著作權保護.

    TAIR相關文章

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回饋